234 related articles for article (PubMed ID: 28706912)
1. Diagnosis and prognosis-review of biomarkers for mesothelioma.
Sun HH; Vaynblat A; Pass HI
Ann Transl Med; 2017 Jun; 5(11):244. PubMed ID: 28706912
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
3. Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network.
Pass HI; Alimi M; Carbone M; Yang H; Goparaju CM
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2524-2540. PubMed ID: 32699075
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
Tsim S; Kelly C; Alexander L; McCormick C; Thomson F; Woodward R; Foster JE; Stobo DB; Paul J; Maskell NA; Chalmers A; Blyth KG
BMJ Open; 2016 Nov; 6(11):e013324. PubMed ID: 27884852
[TBL] [Abstract][Full Text] [Related]
5. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
7. Serum mesothelin and other biomarkers: what have we learned in the last decade?
Cristaudo A; Bonotti A; Guglielmi G; Fallahi P; Foddis R
J Thorac Dis; 2018 Jan; 10(Suppl 2):S353-S359. PubMed ID: 29507805
[TBL] [Abstract][Full Text] [Related]
8. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
10. Mesothelioma Biomarkers: Discovery in Search of Validation.
Pass HI; Alimi M; Carbone M; Yang H; Goparaju CM
Thorac Surg Clin; 2020 Nov; 30(4):395-423. PubMed ID: 33012429
[TBL] [Abstract][Full Text] [Related]
11. [Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].
Scherpereel A; Grigoriu BD; Astoul P
Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S183-90. PubMed ID: 18971844
[TBL] [Abstract][Full Text] [Related]
12. Serum diagnostic markers for malignant pleural mesothelioma: a narrative review.
Wang JJ; Yan L
Transl Cancer Res; 2022 Dec; 11(12):4434-4440. PubMed ID: 36644178
[TBL] [Abstract][Full Text] [Related]
13. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
14. Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.
Fujimoto N; Gemba K; Asano M; Wada S; Ono K; Ozaki S; Kishimoto T
Exp Ther Med; 2010 Mar; 1(2):313-317. PubMed ID: 22993544
[TBL] [Abstract][Full Text] [Related]
15. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
Sorino C; Mondoni M; Marchetti G; Agati S; Inchingolo R; Mei F; Flamini S; Lococo F; Feller-Kopman D
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002620
[TBL] [Abstract][Full Text] [Related]
16. Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma.
Ferrari L; Iodice S; Cantone L; Dallari B; Dioni L; Bordini L; Palleschi A; Mensi C; Pesatori AC
Med Lav; 2022 Dec; 113(6):e2022052. PubMed ID: 36475505
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
18. [New diagnostic markers for malignant pleural mesothelioma].
Grigoriu BD; Grégoire M; Chahine B; Scherpereel A
Bull Cancer; 2008 Feb; 95(2):177-84. PubMed ID: 18304902
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Chen Z; Gaudino G; Pass HI; Carbone M; Yang H
Transl Lung Cancer Res; 2017 Jun; 6(3):259-269. PubMed ID: 28713671
[TBL] [Abstract][Full Text] [Related]
20. Soluble mesothelin-related protein in malignant pleural mesothelioma.
Azim HA; Gaafar R; Abdel Salam I; El-Guindy S; Elattar I; Ashmawy A; Khorshid O
J Egypt Natl Canc Inst; 2008 Sep; 20(3):224-9. PubMed ID: 20424652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
